A detailed history of Boston Partners transactions in Abb Vie Inc. stock. As of the latest transaction made, Boston Partners holds 4,186,277 shares of ABBV stock, worth $852 Million. This represents 0.93% of its overall portfolio holdings.

Number of Shares
4,186,277
Previous 1,173,542 256.72%
Holding current value
$852 Million
Previous $214 Million 236.0%
% of portfolio
0.93%
Previous 0.26%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $466 Million - $545 Million
3,012,735 Added 256.72%
4,186,277 $718 Million
Q1 2024

May 13, 2024

SELL
$159.82 - $182.1 $4.68 Million - $5.33 Million
-29,272 Reduced 2.43%
1,173,542 $214 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $12.9 Million - $14.5 Million
-93,821 Reduced 7.24%
1,202,814 $186 Million
Q3 2023

Nov 07, 2023

SELL
$133.59 - $154.65 $6.45 Million - $7.47 Million
-48,271 Reduced 3.59%
1,296,635 $193 Million
Q2 2023

Aug 10, 2023

SELL
$132.51 - $164.9 $213 Million - $265 Million
-1,607,247 Reduced 54.44%
1,344,906 $181 Million
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $306 Million - $353 Million
-2,116,654 Reduced 41.76%
2,952,153 $470 Million
Q4 2022

Feb 07, 2023

SELL
$138.31 - $165.87 $150 Million - $179 Million
-1,081,267 Reduced 17.58%
5,068,807 $820 Million
Q3 2022

Nov 09, 2022

BUY
$134.21 - $153.93 $23.4 Million - $26.8 Million
174,102 Added 2.91%
6,150,074 $827 Million
Q2 2022

Aug 10, 2022

BUY
$137.62 - $174.96 $75.6 Million - $96.1 Million
549,279 Added 10.12%
5,975,972 $913 Million
Q1 2022

May 10, 2022

SELL
$131.98 - $163.75 $1.7 Million - $2.11 Million
-12,866 Reduced 0.24%
5,426,693 $881 Million
Q4 2021

Feb 04, 2022

BUY
$107.43 - $135.93 $40.7 Million - $51.6 Million
379,250 Added 7.49%
5,439,559 $737 Million
Q3 2021

Nov 05, 2021

BUY
$106.4 - $120.78 $62.7 Million - $71.2 Million
589,506 Added 13.19%
5,060,309 $546 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $123 Million - $137 Million
1,168,684 Added 35.39%
4,470,803 $504 Million
Q1 2021

May 10, 2021

BUY
$102.3 - $112.62 $43 Million - $47.3 Million
420,355 Added 14.59%
3,302,119 $357 Million
Q4 2020

Feb 04, 2021

BUY
$80.49 - $108.67 $221 Million - $298 Million
2,742,063 Added 1962.81%
2,881,764 $309 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $1.9 Million - $2.23 Million
-22,115 Reduced 13.67%
139,701 $12.2 Million
Q2 2020

Aug 12, 2020

SELL
$73.37 - $98.18 $3.63 Million - $4.85 Million
-49,446 Reduced 23.41%
161,816 $15.9 Million
Q1 2020

May 13, 2020

BUY
$64.5 - $97.79 $194,596 - $295,032
3,017 Added 1.45%
211,262 $16.1 Million
Q4 2019

Feb 05, 2020

SELL
$72.13 - $90.25 $2.66 Million - $3.33 Million
-36,926 Reduced 15.06%
208,245 $18.4 Million
Q3 2019

Nov 20, 2019

SELL
$62.98 - $75.72 $375,486 - $451,442
-5,962 Reduced 2.37%
245,171 $18.6 Million
Q2 2019

Aug 09, 2019

BUY
$65.7 - $83.98 $399,915 - $511,186
6,087 Added 2.48%
251,133 $18.3 Million
Q1 2019

May 13, 2019

BUY
$77.14 - $90.79 $18.9 Million - $22.2 Million
245,046 New
245,046 $19.7 Million
Q1 2019

May 03, 2019

SELL
$77.14 - $90.79 $37.2 Million - $43.8 Million
-482,707 Closed
0 $0
Q4 2018

Feb 07, 2019

BUY
$77.85 - $96.01 $37.3 Million - $46 Million
479,461 Added 14770.83%
482,707 $44.5 Million
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $288,601 - $320,834
3,246 New
3,246 $307,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $360B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Boston Partners Portfolio

Follow Boston Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

News

Stay updated on Boston Partners with notifications on news.